-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Immune checkpoint inhibitors ipilimumab, nivolumab and pembrolizumab, as well as BRAF-MEK inhibitors combined with dabrafenib and trametinib in patients with advanced melanoma are in adjuvant measures Reflected by the positive results in the context.
immunity
The European Organization for Research and Treatment of Cancer (EORTC) 1325/KEYNOTE-054 trial evaluated the effect of pembrolizumab vs placebo in patients with high-risk stage III melanoma resection.
This article reports the final analysis results of the secondary efficacy endpoint of the clinical adaptation: the latest data on the survival rate without distant metastasis and the survival rate without recurrence.
The EORTC 1325-MG/KEYNOTE-054 trial is a double-blind, randomized, placebo-controlled phase 3 study, conducted in 123 academic centers and hospitals in 23 countries, and recruited patients over 18 years of age for complete resection.
Survival rates without distant recurrence of patients in different stages (A Figure IIIA, B Figure IIIB, C Figure IIIC)
Survival rates without distant recurrence of patients in different stages (A Figure IIIA, B Figure IIIB, C Figure IIIC)From August 26, 2015 to November 14, 2016, a total of 1019 patients were recruited, of which 514 received pembrolizumab treatment and 505 received placebo.
At a median follow-up of 42.
Recurrence-free survival
Recurrence-free survivalWhether in the intention-to-treat population or in PD-L1 positive patients, the recurrence-free survival rate of the pembrolizumab group was higher than that of the placebo group: 59.
Whether in the intention-to-treat population or in PD-L1 positive patients, the recurrence-free survival rate of the pembrolizumab group was higher than that of the placebo group: 59.
During a median follow-up of 3.
Original source:
Alexander MM Eggermont, et al.
org/10.
1016/S1470-2045(21)00065-6" target="_blank" rel="noopener">Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG / KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
in this message
